NUIG is one of Ireland’s foremost educational and research institutions. With over 17,000 students and more than 2,200 staff, NUIG has a distinguished reputation for teaching and research excellence and NUIG researchers have been successful in coordinating over 31 proposals and partnering on more than 80 proposals under the 7th European Framework Programme.
The Regenerative Medicine Institute (REMEDI, www.remedi.ie) is an embedded biomedical research centre with a central focus on the development of novel therapies for human diseases using adult stem cell and/or gene therapies. REMEDI is the leading stem cell research institute in Ireland with an international reputation in translating basic research findings to clinical applications.
It was established at NUI Galway in 2004 as a Science Foundation Ireland-funded Centre for Science, Engineering and Technology with orthopaedic and cardiovascular indications as the primary disease models underpinned with strong basic research programmes on adult stem cells including bone marrow-derived mesenchymal stem cells (BM-MSCs), haematopoietic stem cells, endothelial progenitors, induced pluripotent stem cells and immunology research to underpin cell therapy.
REMEDI currently has focused research programmes in areas such as stem cell biology, immunology, gene therapy and cell manufacturing. To fulfil its translational mission, REMEDI manages and operates the Centre for Cell Manufacturing Ireland (CCMI), a facility licensed by the Irish Medicines Board to manufacture stem cells for human applications.
Researchers at REMEDI have coordinated three European Framework Programme 7-funded projects (Purstem, Reddstar and Visicort) and one Horizon 2020 project (ADIPOA-2), They have partnered on four FP7 projects (Gamba, Adipoa, Eurostemcell and Decide).
The HRB Clinical Research Facility, Galway (CRFG) began operations in March 2008. Since then, they have initiated 114 studies, recruited over 4,000 participants into these studies, worked with 47 local Principal Investigators and published over 140 articles in peer-review journals. The CRFG is completing studies across a spectrum of disease areas, including cancer, cardiovascular disease and diabetes, haematology, rheumatology, renal, obstetrics, psychiatry, dermatology, infectious diseases and general practice. These studies span a broad range of study designs (early phase clinical trials, Phase III clinical trials, case-control studies, and prospective and retrospective cohort studies), research disciplines (clinical trials of medicinal products to population health research), and collaborations (local, national and international studies). Different studies have required various services from the list above. The CRFG serves as the translational arm of research undertaken by REMEDI.